{"title":"Biotech financing: divide and reset","authors":"","doi":"10.1038/s41587-025-02723-8","DOIUrl":"https://doi.org/10.1038/s41587-025-02723-8","url":null,"abstract":"Today’s uniquely challenging biotech climate may result in a more resilient sector.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"23 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"FDA says GM pigs safe to eat","authors":"","doi":"10.1038/s41587-025-02716-7","DOIUrl":"https://doi.org/10.1038/s41587-025-02716-7","url":null,"abstract":"<p>Pigs genetically modified to resist a devastating virus are now approved for human consumption in the United States. British animal genetics company Genus, based in Basingstoke, announced in April that the US Food and Drug Administration (FDA) had approved its gene-edited pigs after a lengthy review through the agency’s Investigational New Drug regulatory pathway.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"92 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Biotech news from around the world","authors":"","doi":"10.1038/s41587-025-02714-9","DOIUrl":"https://doi.org/10.1038/s41587-025-02714-9","url":null,"abstract":"<p>A new law proposed by the Federal Council would ease restrictions on plants developed through new genomic techniques such as CRISPR. Currently in Switzerland, such plants are treated similarly to those developed through conventional genetic engineering, including an ongoing moratorium on cultivation. If passed, the Breeding Technologies Act would enact a risk-based authorization system that reflects the potential of new breeding technologies and the need for appropriate safeguards.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"43 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Organoids","authors":"","doi":"10.1038/s41587-025-02698-6","DOIUrl":"https://doi.org/10.1038/s41587-025-02698-6","url":null,"abstract":"Recent patents relating to the production, culture and use of organoids.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"229 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Infant receives the first customized CRISPR therapy","authors":"Iris Marchal","doi":"10.1038/s41587-025-02719-4","DOIUrl":"https://doi.org/10.1038/s41587-025-02719-4","url":null,"abstract":"<p>Base and prime editors promise to correct nearly all known pathogenic variants, but their therapeutic development is restricted to a handful of recurrent mutations owing to the high cost of bringing gene therapies to market. Writing in the <i>New England Journal of Medicine</i>, Musunuru et al. report on the rapid development of a customized base-editing therapy, provided to an infant born with a rare disease and delivered in vivo to hepatocytes through lipid nanoparticles.</p><p>The patient, who was diagnosed with a rare metabolic disease of the urea cycle known as carbamoyl phosphate synthetase 1 (CPS1) deficiency that prevents the proper breakdown of protein from food, received the first dose of base-editing therapy at just seven months of age. Within two months, the authors developed a cell line harboring two <i>CPS1</i> variants identified in the patient’s genome and screened various adenine base editors with guide RNAs tiling one of those <i>CPS1</i> variants. They selected the most efficient and precise base editor, called k-abe. Five months after birth, they assessed the in vivo efficiency of k-abe in a patient-specific mouse model, showing up to 42% whole-liver corrective editing. Safety studies in nonhuman primates and analyses of off-target editing in hepatocytes cleared the way for regulatory approval.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"35 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"England poised to green-light precision breeding","authors":"","doi":"10.1038/s41587-025-02715-8","DOIUrl":"https://doi.org/10.1038/s41587-025-02715-8","url":null,"abstract":"<p>The UK government is close to approving rules for precision-bred plants in England. In May, Parliament published draft legislation that will enable a new regulatory system, as set out in the Genetic Technology (Precision Breeding) Act 2023.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"10 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"People","authors":"","doi":"10.1038/s41587-025-02703-y","DOIUrl":"https://doi.org/10.1038/s41587-025-02703-y","url":null,"abstract":"Recent moves of note in and around the biotech and pharma industries.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"598 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Thinking about a move from academia to industry? Look before you leap","authors":"William N. Hait","doi":"10.1038/s41587-025-02700-1","DOIUrl":"https://doi.org/10.1038/s41587-025-02700-1","url":null,"abstract":"To those considering a change in careers from academia to the pharmaceutical industry, here are the keys to a successful transition.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"10 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Limitations of cell embedding metrics assessed using drifting islands","authors":"Hanchen Wang, Jure Leskovec, Aviv Regev","doi":"10.1038/s41587-025-02702-z","DOIUrl":"https://doi.org/10.1038/s41587-025-02702-z","url":null,"abstract":"<p>Biological studies rely on embeddings of single-cell profiles but assessing the quality of these embeddings is challenging. Here we show that current evaluation metrics are incomplete by training a three-layer perceptron, Islander. Islander outperforms all leading embedding methods on a diverse set of cell atlases but it distorts biological structures, limiting its use for biological discovery. We then present a new metric, scGraph, to help flag such distortions.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"14 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144260351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Individualized mRNA cancer vaccines make strides","authors":"","doi":"10.1038/s41587-025-02708-7","DOIUrl":"https://doi.org/10.1038/s41587-025-02708-7","url":null,"abstract":"The first cancer vaccines matched to a person’s unique tumor neoantigens are forging ahead, with expectations running high as the field awaits results from the first pivotal trial.","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"2 1","pages":""},"PeriodicalIF":46.9,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144252046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}